Pembrolizumab-induced resolving papulosquamous eruption: An enigmatic presentation in a patient with renal cell carcinoma

Abstract

Lenvatinib, a multiple tyrosine receptor kinase inhibitor, and pembrolizumab, an anti-programmed cell death protein 1 humanized antibody, both are indicated in the treatment of renal cell carcinoma (RCC). Both these agents rarely produce cutaneous adverse events. In this instance, a RCC patient who received both medications and experienced a papulosquamous eruption as an uncommon cutaneous side effect of both medications is being reported. The potential drug triggers preceded the symptom onset and the observed symptom resolved on discontinuation of pembrolizumab.